Varicella Vaccine Market by Product Type (Monovalent Varicella Vaccine and Combination Varicella Vaccine), Patient Type (Pediatric Patients and Adult Patients) – Analysis & Forecast 2020-2030

Report ID : 247  |  Published Date : Jun 2020  |  Pages : 150  |  Region : Global  |  Report Code : PH-16

Varicella Vaccine Market Overview and Introduction

Varicella also known as chicken pox, is a highly contagious disease which typically affects children aged 2?8 years, and is caused by the varicella-zoster virus (VZV). The reactivation of VZV in later stages of life leads to a form of viral infection, known as shingles. Immunization against VZV is necessary as chicken pox can lead to serious complications such as bacterial infections, lung infections, and inflammation or infection of brain among others. Immunization with varicella vaccine serves as an effective method for prevention of this disease.

The global varicella vaccine market is mainly driven by improvement in access to vaccines worldwide, innovation in vaccine production, and advent of novel technologies among others. Moreover, rising pediatric and adult population worldwide has played a pivotal role in contributing to growth of the market. However, complex government rules & regulations and high cost involved in vaccine development are likely to restrain the growth of the market to a certain extent.

The global varicella vaccine market can be segmented into product type, patient type, and regions.

Varicella Vaccine Market by Product Type

Based on product type, the market is segmented into monovalent varicella vaccine and combination varicella vaccine. The monovalent varicella vaccine is expected to dominate the varicella vaccine market during the forecast period. The growth of monovalent vaccine segment can be attributed to lower occurrence rate of febrile seizures among children as compared to combination vaccines. Moreover, availability of a large number of monovalent varicella vaccine products have also been a significant factor in propelling the growth of market.

Varicella Vaccine Market by Patient Type

Based on patient type, the market can be segmented into pediatric patients and adult patients. The pediatric patients segment is projected to dominate the global varicella vaccine market during the forecast period owing to high susceptibility of young children who are likely to be infected by the varicella virus, especially children with weakened immune system.

Varicella Vaccine Market by Region

Based on region, the global varicella vaccine market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the varicella vaccine market, followed by Asia Pacific. The growth in North America can be attributed to favorable government healthcare policies, easy access to varicella vaccines and presence of leading vaccine manufacturers in this region.

Varicella Vaccine Market Prominent Players

Some of the prominent players in the global varicella vaccine market include Merck & Co., Inc., GlaxoSmithKline plc., BIKEN, Green Cross, Zuventus HealthCare Ltd., Sinovac Biotech Ltd., Changchun Baike Biotechnology Co., Ltd., SK chemicals (SK bioscience) and BIO-MED